Abstract:Objective To investigate the effect of transcatheter arterial chemoembolization (TACE)combined with Sorafenib in the treatment of primary liver cancer.Methods From January 2014 to October 2017,60 patients with primary large hepatocellular carcinoma were selected as the research objects,and divided into study group and control group according to different treatment methods,30 cases in each group.Patients in the control group were treated with TACE alone,while patients in the study group were treated with Sorafenib on the basis of TACE.The therapeutic effect,liver function index and incidence of adverse reactions were compared between the two groups.Results The total clinical effective rate in the study group was significantly higher than that in the control group (P<0.05).There was no significant difference between the two groups in ALB,ALT and TBil before operation (P>0.05).After treatment,ALT and TBil in the study group were significantly better than those in the control group (P<0.05).The incidence of adverse reactions in the study group was significantly lower than that in the control group(P<0.05).Conclusion Compared with single treatment,combination of application of Sorafenib on the basis of TACE treatment in patients with primary liver cancer achieves more significant treatment effect,can effectively improve patients′liver function index with higher drug safety and no obvious side effects,which has high clinical application value.